Here's what we'll cover
Here's what we'll cover
If you're paying hundreds of dollars a month for Ozempic, you're not alone, and you're not imagining it. Maryland has become one of the latest states to push back on those costs, announcing limits on what patients pay for Ozempic as prescription prices continue their upward climb.
Whether you live in Maryland or not, this development signals something important: policymakers are starting to respond to a crisis that GLP-1 users have been living with for years.
What Maryland's Payment Limits Actually Do
Maryland's move sets a cap on out-of-pocket costs for Ozempic, primarily targeting patients enrolled in state-regulated insurance plans. The intent is to prevent patients from being priced out of a medication that, for many, is medically necessary for managing type 2 diabetes or obesity.
This kind of cost-sharing limit doesn't change the list price of the drug itself. What it does is restrict how much of that cost an insurer can pass directly to the patient through copays, coinsurance, or deductibles.
For patients in eligible Maryland plans, this could mean meaningful monthly savings. But the details matter: not all insurance plans are subject to state regulation, and self-insured employer plans, for example, fall under federal rules rather than state law. That's a gap that affects millions of people.
Who Is Most Likely to Benefit?
Patients most likely to see direct relief are those with individual or small-group plans purchased through Maryland's state insurance marketplace. People on Medicaid may also see changes depending on how the state applies this to its managed care programs.
Federal employees, people with large employer coverage, and those paying entirely out of pocket will not automatically benefit from this specific policy.
Why GLP-1 Costs Have Gotten So High
Semaglutide, the active ingredient in both Ozempic and Wegovy, has become one of the most prescribed drugs in the United States. Tirzepatide, found in Mounjaro and Zepbound, isn't far behind.
Manufacturer list prices for these medications often exceed $900 to $1,000 per month before any insurance adjustment. That's before accounting for the fact that many insurers still don't cover GLP-1s for weight loss at all, even as clinical evidence supporting their use continues to grow.
The demand surge from both diabetes and obesity indications, combined with limited competition (no generics exist yet for these drugs), has kept prices elevated. States like Maryland are stepping in precisely because federal action on drug pricing has been slow and inconsistent.
The Coverage Gap Is Still Real
Even with a state cap on patient costs, you still need insurance that covers Ozempic in the first place. Coverage for semaglutide varies widely:
What This Means If You're Outside Maryland
Most readers won't qualify for Maryland's specific policy. But the broader lesson is worth applying wherever you live.
Costs are high, coverage is inconsistent, and waiting for your state or the federal government to fix it may mean months or years of unaffordable prescriptions. That means you need a proactive strategy right now.
Here's where to start.
Step 1: Check What Your Plan Actually Covers
Don't assume your insurance covers GLP-1 medications. Call your insurer or check your formulary (the official list of covered drugs) directly. Ask specifically about Ozempic for diabetes versus Wegovy for weight management. These are different approvals and often covered under different rules.
If your doctor prescribed Ozempic off-label for weight loss rather than prescribing Wegovy, that distinction may affect what your insurance will pay.
Step 2: Ask About Manufacturer Savings Programs
Novo Nordisk, the maker of Ozempic and Wegovy, offers savings cards and patient assistance programs. Eligibility requirements apply, and these programs have income limits and insurance restrictions, but they can significantly reduce costs for qualifying patients.
Eli Lilly offers similar programs for Mounjaro and Zepbound. These aren't permanent solutions, but they can bridge the gap while you sort out long-term coverage.
You can find links to current offers through our GLP-1 Coupons page.
Step 3: Compare Telehealth Providers
The provider you choose has a direct impact on your total cost. Some telehealth platforms charge high monthly fees on top of the drug cost. Others work with compounding pharmacies or negotiate better pricing for their patients.
Using a comparison resource to evaluate your options before committing to a provider can save you hundreds per month. Our Best Providers guide breaks down what each platform charges, how they handle prescriptions, and what's included in the monthly cost.
Questions to Ask Your Doctor Before Your Next Refill
If you're currently on a GLP-1 medication or considering starting one, bring these questions to your next appointment:
On coverage and cost:
- Is my current prescription covered under the diabetes or weight loss indication?
- Would switching to a different branded medication improve my insurance coverage?
- Are there prior authorization requirements I should be aware of?
On alternatives:
- Is a lower dose appropriate while I manage costs?
- Is there a clinical reason to switch between semaglutide and tirzepatide?
- Would a patient assistance program be appropriate for my situation?
These conversations don't have to be awkward. Providers who specialize in GLP-1 prescribing expect cost to be part of the discussion.
The Compounding Question: Where Things Stand Now
For much of 2023 and 2024, compounded semaglutide offered a lower-cost alternative for patients who couldn't afford brand-name Ozempic or Wegovy. Compounding pharmacies produced versions of the drug at a fraction of the branded price.
That window has narrowed significantly. The FDA removed semaglutide from its drug shortage list, which triggered restrictions on compounded versions. Some pharmacies have shifted to tirzepatide compounding, though that space is also under regulatory scrutiny.
This matters for cost planning. If you were relying on compounded GLP-1s as a long-term strategy, the landscape has shifted. Working with a telehealth provider that stays current on FDA guidance is increasingly important.
State-Level Action: A Growing Trend
Maryland isn't the first state to act, and it likely won't be the last. Several states have explored or enacted drug pricing legislation targeting high-cost medications, and GLP-1 drugs have increasingly become a focal point given their prescription volume.
Colorado, for example, has pursued broader out-of-pocket cost caps on insulin and other drugs. California has examined GLP-1 coverage mandates for Medicaid. These efforts are fragmented and vary significantly in scope, but they reflect a real shift in political will.
What this means practically: the affordability picture for GLP-1 users could improve over the next few years, but meaningful relief isn't guaranteed or uniform. Patients who stay informed about their specific state's policies are better positioned to take advantage of changes as they happen.
No waiting list. No insurance needed.
Frequently Asked Questions
What does Maryland's Ozempic payment limit actually mean for patients?
Maryland's payment limit caps how much patients in state-regulated insurance plans must pay out-of-pocket for Ozempic. It doesn't lower the drug's list price, but it restricts how much of that cost insurers can pass to patients through copays or coinsurance. Patients in qualifying plans may see lower monthly costs as a result.
Does Maryland's Ozempic cap apply to everyone in the state?
No. The cap applies primarily to patients in state-regulated individual and small-group insurance plans. People with self-insured employer plans, federal coverage, or no insurance are not automatically covered by this state-level policy, as those plans fall under federal rather than state jurisdiction.
How much does Ozempic cost without insurance?
Without insurance, Ozempic's list price is typically over $900 per month for a standard dose. Actual out-of-pocket costs vary based on pharmacy, dose, and whether you use any manufacturer savings programs or coupons. Wegovy, the weight loss version of semaglutide, has a similar list price.
Can I still get compounded semaglutide to save money?
Access to compounded semaglutide has become significantly more restricted since the FDA removed semaglutide from its drug shortage list in 2025. Many compounding pharmacies have had to discontinue these products. Some providers now offer compounded tirzepatide, but that space is also under active FDA review.
What's the difference between Ozempic and Wegovy for insurance purposes?
Ozempic is FDA-approved for type 2 diabetes and is more commonly covered by insurance under that indication. Wegovy contains the same active ingredient (semaglutide) but is approved specifically for weight management. Many insurance plans cover Ozempic but exclude Wegovy, so the indication on your prescription can significantly affect your coverage and costs.
Are other states following Maryland's lead on GLP-1 drug pricing?
Yes, several states have been pursuing drug pricing reforms that could affect GLP-1 costs. Colorado and California have explored related policies covering insulin, other high-cost drugs, and Medicaid coverage for weight loss medications. Progress varies by state, and no comprehensive federal policy currently addresses GLP-1 out-of-pocket costs uniformly.